Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations

Impact Factor: 20.3
Citescore: 35
All metrics >>

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via X and Facebook.

Listen to the ARD Podcast and subscribe in all podcast platforms, including Apple Podcasts, Amazon Music and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Current Issue

Latest EULAR Recommendations

Involvement of patient research partners in rheumatology research

EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update

Management of psoriatic arthritis with pharmacological therapies

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

3D rendered photo of rheumatological disease affecting the hand

Imaging in diagnosis and management of CiAs in clinical practice

2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

Non-pharmacological core management of hip and knee osteoarthritis

EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Latest Articles

Letter:

Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis

27 June 2024

Systemic lupus erythematosus:

Haematopoietic stem cell-derived immune cells have reduced X chromosome inactivation skewing in systemic lupus erythematosus

27 June 2024

Letter:

Cardiac valve immune profiling in non-radiographic axial spondyloarthritis

26 June 2024

Reviews:

B-cell depletion in autoimmune diseases

20 June 2024

Myositis:

Pathological autoantibody internalisation in myositis

20 June 2024

Articles by Topic

View full list

Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

All EULAR recommendations are free to access.

Each recommendation also has an accompanying lay summary, which is also free to access.

Video Abstract

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

16 April 2024

Discussion: Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling, including apoptotic, innate and adaptive mechanisms that play key roles in SLE immunopathogenesis.

Find out more